The research trend is shifting from over-the-counter immunotherapy, intensity-modulated radiotherapy, and concurrent radiochemotherapy to antitumor activity, PD-L1/PD-1, and the tumor microenvironment. The gene discussed is CD274; the disease is neoplasm.